Inhalation

INH0426

Issue link: https://www.e-digitaleditions.com/i/1544305

Contents of this Issue

Navigation

Page 34 of 47

Inhalation April 2026 33 Accessing an XCT service provider can help bridge the gap in matching the technical capabilities of XCT technique with the application needs of the pharmaceutical industry. Services may include sam- ple preparation, instrument selection, image analysis and data interpretation methods, chosen with spe- cific understanding of the scientific problem that the formulator or pharmaceutical materials scientist needs to address. When XCT expertise is coupled with pharmaceu- tical science to design the analytical program, it is possible to translate X-ray tomographic images and raw data into valuable microstructural insights with quantitative metrics that support formulation and manufacturing decisions. References 1. Rajkumar AD, Reynolds GK, Wilson D, Wren SAC, Salman AD. e effect of roller compaction and tableting stresses on pharmaceutical tablet performance. Powder Technology. 2019 January; 341: 23-37. 2. Yassin S, Goodwin DJ, Anderson A, Sibik J, Ian Wilson D, Gladden LF, et al. e disintegration pro- cess in microcrystalline cellulose based tablets, Part 1: Influence of temperature, porosity and superdis- integrants. Journal of Pharmaceutical Sciences. 2015 October; 104: 3440-3450. 3. Farias G, Ganley W, Deddie HJ, Kippax P, Shur J, Price R. Investigating the microstructure of dry pow- der inhalers using orthogonal analytical approaches. In Drug Delivery to the Lungs; 2017. p. 262-265. 4. Price R, Shur J, Ganley W, Farias G, Fotaki N, Conti DS, et al. Development of an aerosol dose col- lection apparatus for in vitro dissolution measure- ments of orally inhaled drug products. e AAPS Journal. 2020 February; 22(2): 47. optics and detector instrumentation of relevance to pharmaceutical materials across multiple instrument types. Assessing and validating the utility of different instruments can bring its own challenges, since the quality of data generated is affected by the sample preparation methodology. is can require a demo lab that has an ability to incorporate into the data generation process an understanding of the impact of handling and storage (e.g., humidity-mediated changes) on the measured pharmaceutical material properties. In most instances, the clarity needed to support an instrument purchase is difficult to obtain without engaging a XCT service provider since the low number of samples that can be run in demo labs is normally insufficient to meet QA-QC testing requirements of the pharmaceutical industry. Figure 7 Microstructural view of a Seretide 250 blister, with lactose colored gray and the drug rendered in color.

Articles in this issue

Links on this page

view archives of Inhalation - INH0426